BaseSpace
Correlation Engine 2.0
Import Your Data
QuickView

FAQ

More QuickView FAQs

Back to top
Clear Search sequence regions
(e.g. Apoptosis, Hepatitis, Leukocyte, Early pregnancy factor, Acetaminophen, rs2230926, EGFR)
Bookmark Forward

QuickView for epothilone (compound)


Genetic Markers

Most Correlated Genes

  1. CRIP1
  2. ANO1
  3. DLK1
  4. TXNIP
  5. LPL
Explore Genetic Markers Results

Pathway Enrichment

Most Correlated Biogroups

  1. cytosol
  2. organic cyclic compound binding
  3. heterocyclic compound binding
  4. regulation of nitrogen compound metabolic process
  5. organic cyclic compound metabolic process
Explore Pathway Enrichment Results

Curated Studies

Most Correlated Studies

  1. Invasive breast adenocarcinomas before Ixabepilone or Paclitaxel treatment
  2. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
  3. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
  4. L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Explore Curated Studies Results

Literature

Most Relevant Literature

  1. Co-cultivation of Sorangium cellulosum strains affects cellular growth and biosynthesis of secondary…
  2. Altered TUBB3 expression contributes to the epothilone response of mitotic cells.
  3. The epothilones: new therapeutic agents for castration-resistant prostate cancer.
  4. Epothilones in prostate cancer.
  5. New epothilone congeners from Sorangium cellulosum strain So0157-2.
Explore Literature Results

Clinical Trials

Most Relevant Clinical Trials

  1. Epothilone in Recurrent Glioblastoma Patients
  2. Epothilone B in Treating Patients With CNS Metastases From Breast Cancer
  3. Epothilone D as Second-Line Treatment for Patients With Advanced or Metastatic Refractory Colorectal…
  4. A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
  5. Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
Explore Clinical Trials Results
  • Copyright © 2024 Illumina Inc. All rights reserved.